U.S. Stem Cell, Inc.
USRM
Rank in Stocks
#33836
U.S. Stem Cell, Inc. is a biotechnology firm dedicated to the advancement and... U.S. Stem Cell, Inc. is a biotechnology firm dedicated to the advancement and commercialization of autologous cellular therapies throughout the United States. Its core mission is to address a range of medical conditions, including both chronic and acute forms of heart damage, along with various vascular and autoimmune disorders. Among its leading experimental treatments are MyoCell, a clinical-stage therapy designed to utilize a patient's own muscle cells to regenerate scar tissue within the heart, aiming to enhance cardiac function for individuals suffering from chronic heart failure. Another significant offering is AdipoCell, a cell therapy also derived from the patient's own body, developed to combat conditions such as acute myocardial infarction, persistent heart ischemia, and ischemia affecting the lower limbs. The company's developmental pipeline also features MyoCell SDF-1, another autologous cellular therapy derived from muscle, intended to boost cardiac performance in chronic heart failure patients. Furthermore, U.S. Stem Cell is actively developing MyoCath, an innovative deflecting-tip needle injection catheter specifically engineered to deliver therapeutic cells directly into heart tissue, addressing chronic heart ischemia and congestive heart failure. Beyond its product development, the company offers a suite of services, including training programs in regenerative medicine and cell therapy for both medical professionals and patients. It also facilitates cell collection and storage, provides specialized kits for cell collection and treatment for both human and veterinary applications, and manages its own cell therapy clinic. This clinic delivers cellular treatments for a broad spectrum of conditions, such as neurological, autoimmune, orthopedic, and degenerative disorders. Previously known as Bioheart, Inc., the company adopted its current name, U.S. Stem Cell, Inc., in October 2015. Established in 1999, its corporate headquarters are situated in Sunrise, Florida.
Share Price
$0.0003
Last synced: 2026-11-09
Market Cap
$192.45K
Change (1 day)
200.00%
Change (1 year)
200.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade U.S. Stem Cell, Inc. (USRM)
Category
Healthcare
EPS for U.S. Stem Cell, Inc. (USRM)
EPS as of December 2022 TTM: $-0.01
According to U.S. Stem Cell, Inc.'s latest financial reports, its current EPS (TTM) is $-0.01. At the end of 2022 the company had an EPS of 0.00, an increase over its 2021 EPS of $-0.01.
EPS history for U.S. Stem Cell, Inc. from 2002 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.01 | -32.39% |
| 2022 | 0.00 | -32.39% |
| 2021 | $-0.01 | 5.97% |
| 2020 | $-0.01 | -33.00% |
| 2019 | $-0.01 | 69.49% |
| 2018 | $-0.01 | -47.79% |
| 2017 | $-0.01 | -87.44% |
| 2016 | $-0.09 | -95.00% |
| 2015 | $-1.80 | -60.95% |
| 2014 | $-4.61 | -63.06% |
| 2013 | $-12.48 | -54.49% |
| 2012 | $-27.42 | -66.67% |
| 2011 | $-82.28 | -56.68% |
| 2010 | $-189.92 | -12.82% |
| 2009 | $-217.84 | -77.62% |
| 2008 | $-973.41 | -28.83% |
| 2007 | $-1.37K | 24.67% |
| 2006 | $-1.10K | 59.49% |
| 2005 | $-687.81 | 14.63% |
| 2004 | $-600.02 | -19.99% |
| 2003 | $-749.97 | -51.34% |
| 2002 | $-1.54K | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -313,300.00% |
US
|
|
| $-7.07 | 141,300.00% |
US
|
|
| $-5.29 | 105,700.00% |
AU
|
|
| $12.88 | -257,702.00% |
BE
|
|
| $21.56 | -431,300.00% |
NL
|
Questions about U.S. Stem Cell, Inc.'s earnings per share (EPS)
What is U.S. Stem Cell, Inc.'s earnings per share (EPS)?
U.S. Stem Cell, Inc.'s earnings per share (EPS) over the last twelve months is $-0.01, as of Dec 2022.
What was U.S. Stem Cell, Inc.'s earnings per share (EPS) in 2022?
In 2022, U.S. Stem Cell, Inc.'s earnings per share (EPS) was 0.00, compared with $-0.01 in 2021.
How has U.S. Stem Cell, Inc.'s earnings per share (EPS) changed since 2017?
From 2017 to 2022, U.S. Stem Cell, Inc.'s earnings per share (EPS) was highest in 2022 (0.00) and lowest in 2021 ($-0.01).
How does U.S. Stem Cell, Inc.'s earnings per share (EPS) compare with similar companies?
U.S. Stem Cell, Inc.'s earnings per share (EPS) ($-0.01) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.